Applying Patient-Centered Management Strategies to Immune Thrombocytopenia: Allison Miller Imahiyerobo, APN
Selma Khenissi, MPS
Expert Analysis
Immune thrombocytopenia (ITP) is an acquired immune-mediated disorder defined as a peripheral blood platelet count <100 x 109/L with no known cause. In this excerpt of the transcript from her nursing continuing professional development (NCPD)–approved activity, Immune Thrombocytopenia: Evolving Treatment Paradigms and Patient-Centered Care, Alli...
Sacituzumab Govitecan for Advanced Urothelial Cancer: Petros Grivas, MD, PhD
Keira Smith
FDA Updates
Recently, the FDA granted accelerated approval to sacituzumab govitecan (Trodelvy®, Immunomedics), an antibody-drug conjugate, for patients with locally advanced or metastatic urothelial cancer whose disease progressed following treatment with platinum-containing chemotherapy and a programmed cell death protein 1 (PD-1)/programmed death ligand-1 (P...
Camrelizumab for Advanced Squamous Non-Small Cell Lung Carcinoma: Caicun Zhou, MD, PhD
Kristin Wright, PharmD
Expert Analysis
Recently, the results of a phase 3 trial on camrelizumab were published in the Journal of Thoracic Oncology and presented at the European Lung Cancer Virtual Congress 2021. Camrelizumab was studied in the randomized, double-blind, multicenter trial as a treatment for advanced squamous non-small cell lung carcinoma (NSCLC). Patients with stages IIIB...
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Nina Shah, MD
Kristin Wright, PharmD
Featured Exclusive
Recently, the FDA approved idecabtagene vicleucel (Abecma®, Bristol Myers Squibb) for patients with relapsed or refractory multiple myeloma who have already been treated with four or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. The approval was based on KarMMa, a phase 2 t...
Sacituzumab Govitecan for Triple-Negative Breast Cancer: Aditya Bardia, MD
Kristin Wright, PharmD
Expert Analysis
Recently, the FDA granted regular approval to sacituzumab govitecan (Trodelvy®, Immunomedics, Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously been treated with two or more systemic therapies, at least one of them for metastatic disease. The FDA had previously granted accel...
Melphalan Flufenamide for Multiple Myeloma: Paul Richardson, MD
Elizabeth Heller, PhD
Featured Exclusive
Melphalan flufenamide, a newly approved peptide-drug conjugate for multiple myeloma, specifically targets chemotherapy to tumor cells like a warhead on a guided missile. In the following interview, Dr. Paul Richardson, the Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cance...
Pembrolizumab for Esophageal or Gastroesophageal Junction Carcinoma: Ken Kato, MD, PhD
Kristin Wright, PharmD
Expert Analysis
Recently, the FDA approved pembrolizumab (Keytruda®, Merck Sharp & Dohme Corp.) in combination with platinum/fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal junction (GEJ) carcinoma who do not qualify for surgical resection or definitive chemoradiation. The approval was based o...
Breast Cancer Metastases and Survival Outcomes: Wenbin Zhou, MD, PhD
Keira Smith
Expert Analysis
Approximately 3%–8% of patients with newly diagnosed breast cancer have synchronous distant metastases, which are associated with a poor prognosis. Because therapeutic strategies are guided by the status of lymph node metastases, accurate assessment is necessary in order to select the appropriate treatment for different patients. In a study recentl...
Nivolumab/Cabozantinib for Renal Cell Carcinoma: David Braun, MD, PhD, and Wenxin (Vincent) Xu, MD
Kristin Wright, PharmD
Expert Analysis
Recently, the results of a phase 3 trial on nivolumab/cabozantinib were published in the New England Journal of Medicine. The study (CheckMate 9ER) compared the efficacy and safety of nivolumab/cabozantinib with those of sunitinib in adult patients with previously untreated advanced clear cell renal cell carcinoma (RCC). The trial results demonstra...
Lorlatinib for Metastatic ALK-Positive Non-Small Cell Lung Cancer: Todd Bauer, MD
Elizabeth Heller, PhD
Expert Analysis
Recently, the FDA granted approval to lorlatinib (Lorbrena®, Pfizer, Inc.) for the treatment of patients with anaplastic lymphoma kinase (ALK)–positive non-small cell lung cancer. This subset of lung cancers defined by their chromosomal rearrangements of the ALK gene are highly sensitive to small-molecule ALK tyrosine kinase inhibitors (TKIs). Lorl...
Acupuncture for Managing Chronic Musculoskeletal Pain in Cancer Survivors: Jun Mao, MD, MSCE
Keira Smith
Expert Analysis
Nearly 50% of cancer survivors are undertreated for chronic pain, a condition which negatively impacts cancer-related outcomes, physical function, and quality of life. Due to the challenges of the opioid crisis, non-pharmacologic alternatives for pain management in cancer survivors are greatly needed. In the randomized PEACE trial, results of which...
Diagnosing Myelodysplastic Syndromes With David Steensma, MD, FACP; Reza Nejati, MD; and Ilene Galinsky, BSN, MSN, ANP-C
Keira Smith
Expert Analysis
A complex group of heterogenous hematopoietic disorders, myelodysplastic syndromes (MDS) often go unrecognized and undiagnosed. Accurate diagnosis and risk assessment for this condition require a myriad of tests and an in-depth evaluation of symptoms. In this excerpt from their continuing medical education (CME)/nursing continuing professional deve...
Axicabtagene Ciloleucel for Follicular Lymphoma: Julio Chavez, MD
Kristin Wright, PharmD
Expert Analysis
Recently, the FDA approved axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. The approval was based on results from ZUMA-5, a phase 2 trial i...
Managing Treatment-Related Adverse Effects of Multiple Myeloma: Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN
Elizabeth Heller, PhD
Expert Analysis
Multiple myeloma is a cancer of the bone marrow plasma cells that causes the overproduction of monoclonal immunoglobulins, which can lead to organ damage. In this excerpt of the transcript from her nursing continuing professional development (NCPD)-approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centere...
Tirbanibulin for Actinic Keratosis: George Martin, MD
Kristin Wright, PharmD
Expert Analysis
Recently, the results of two phase 3 trials on tirbanibulin were published in the New England Journal of Medicine. Tirbanibulin was studied in two identically designed double-blind trials as a treatment for actinic keratosis, a precursor of cutaneous squamous-cell carcinoma. Adults with actinic keratosis lesions on their face or scalp received eith...
Enfortumab Vedotin for Urothelial Carcinoma: Thomas Powles, MD, MBBS, MRCP
Keira Smith
Expert Analysis
For patients with locally advanced or metastatic urothelial carcinoma, treatment options are limited after progression on chemotherapy and immune checkpoint inhibitors, and survival rates remain low. In the phase 3 EV-301 trial, results of which were recently presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Sympos...
Cemiplimab for First-line Treatment of Advanced Non-Small Cell Lung Cancer: Ahmet Sezer, MD
Elizabeth Heller, PhD
Expert Analysis
Recently, the FDA granted approval to cemiplimab-rwlc (Libtayo®, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with advanced non-small lung cancer cell (NSCLC) whose tumors express programmed death ligand 1 (PD-L1) in at least 50% of their cells and whose tumors do not have aberrations in epidermal growth factor receptor...
Shifting Paradigm in Treating Metastatic Prostate Cancer: Judd W. Moul, MD, FACS
Kristin Wright, PharmD
Expert Analysis
The management of metastatic prostate cancer has undergone a paradigm shift over the last few years. Landmark trials including CHAARTED and STAMPEDE have provided evidence for using therapies that were previously reserved for castration-resistant prostate cancer for patients with hormone-sensitive prostate cancer. In this excerpt of the transcript ...
Evaluating Symptoms and Treatment Options for Myelofibrosis: Alice Lynn, ANP, and Dawn Urbanovsky, RN, BSN, OCN®
Keira Smith
Expert Analysis
Myelofibrosis, a myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, and extramedullary hematopoiesis, is a very challenging disease to treat, with patients experiencing progressive symptoms that can negatively impact their quality of life. In this excerpt of the transcript from their nursing continuing professional devel...
Cemiplimab Approval for Locally Advanced/Metastatic Basal Cell Carcinoma
Keira Smith
Expert Analysis
Recently, the FDA granted approval to cemiplimab (Libtayo®, Regeneron Pharmaceuticals) for the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) who were previously treated with a hedgehog pathway inhibitor (HHI) or who are ineligible for HHI therapy. In this interview, Karl Lewis, MD, Professor of Medical Oncolog...

Copyright © 2022 Oncology Data Advisor. All rights reserved.